MDM2, MDMX and p53 in oncogenesis and cancer therapy

By M. Wade, Yao-Cheng Li, G. Wahl. Nature Reviews. Cancer, 2013

1,215 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Hyper-progressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate (2017, background): “MDM2 amplification is found in about 7% of cancers; it inhibits the p53 tumor suppressor (MDM4 is a homolog of MDM2 that interacts with it and also inhibits p53) (21).”
Exosomes in Cancer Development, Metastasis and Drug Resistance: A Comprehensive Review (2013, neutral): “In tumors, where p53 is functional, it is under tight regulation by the negative regulator MDM2 that promotes its ubiquitin dependent degradation [87].”
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches. (2016, neutral): “The tetrameric state of thismutant can be recovered by binding to tetraguanidiniomethylcalix[4]arene (152).”
TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data (2016, background): “The melanoma cell-line C32 for example has an MDM4 amplification which is known to result in TP53 inhibition via MDM4-TP53 protein–protein interaction [Wade et al., 2013] and may be the reason for C32 insensitivity to TP53-MDM2 inhibitor(s).”